Is it still necessary to take platinib after total thyroid cancer removal?

Whether Platinib is needed after total thyroid cancer resection mainly depends on the patient's specific circumstances, including the type and stage of thyroid cancer, the presence of specific gene mutations (such asRETgene mutations), and the patient's overall health status.

Platinib is an oral, selective RET (Rearranged during Transfection) inhibitor that is mainly used to treat certain types of thyroid cancer, especially those with RET gene mutations. Platinib has shown promising efficacy in advanced or metastatic RET mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer, significantly reducing cancer progression and mortality and improving patients' quality of life.

Different types of thyroid cancer (such as papillary carcinoma, follicular carcinoma, medullary carcinoma, etc.) and different stages (such as early, intermediate, late) have different treatment requirements. Generally speaking, patients with early-stage thyroid cancer who have undergone total resection may not need additional targeted therapy, while patients with advanced disease or those with specific genetic mutations may need to consider it.

The presenceRET gene mutation is a key factor in deciding whether to use platinib. If the RET gene variant is present in a patient's tumor sample, platinib may be an appropriate treatment option.

Factors such as the patient's age, physical condition, liver and kidney function also affect treatment decisions. For example, for patients with poor liver and kidney function, drug dosage may need to be adjusted or alternative treatment options selected.

In addition to targeted therapy, patients after total resection of thyroid cancer may also need to consider other treatment options such as radioactive iodine therapy and chemotherapy. Which option is chosen depends on the patient's specific situation and the doctor's recommendations.